GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OliX Pharmaceuticals Inc (XKRX:226950) » Definitions » Short Interest

OliX Pharmaceuticals (XKRX:226950) Short Interest


View and export this data going back to 2018. Start your Free Trial

What is OliX Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of OliX Pharmaceuticals's Short Interest

For the Biotechnology subindustry, OliX Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OliX Pharmaceuticals's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OliX Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where OliX Pharmaceuticals's Short Interest falls into.


;
;

OliX Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OliX Pharmaceuticals Inc (XKRX:226950) » Definitions » Short Interest
Comparable Companies
XKRX:358570 XKRX:950210 XKRX:347850 XKRX:085660 XKRX:086900 XKRX:115450 XKRX:005250 XKRX:005690 XKRX:215600 XKRX:048410 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
No. 1014 Gwanggyo Ace Tower 1, Daehak 4-ro, Yeongtong-gu, Gyeonggi, Suwon, KOR, 16226
Website
http://www.olixpharma.com
OliX Pharmaceuticals Inc is a clinical stage biotechnology company. It is engaged in developing RNA interference (RNAi) technology therapeutics for dermal, ophthalmic and pulmonary diseases. The company's pipeline products include OLX101, OLX201, OLX301, OLX102, and others.

OliX Pharmaceuticals Headlines

No Headlines